Evidence map›Paper›PMID 40034258›Full record

ArticleBiochemistry and biophysics reports2025

Improving the antimicrobial activity of RP9 peptide through theoretical and experimental investigation.

Mahya Anahid, Karim Mahnam, Behnaz Saffar

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mahya AnahidDepartment of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran.
Karim MahnamDepartment of Biology, Faculty of Science, Shahrekord University, Shahrekord, Iran.
Behnaz SaffarDepartment of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Future threats to humanity may stem from the rise of antimicrobial resistance, which has compromised the effectiveness of existing antibiotics. Antimicrobial peptides possess the ability to directly eliminate pathogens and cancer cells, generally without the development of resistance. Among these peptides is RP9 (RGSALTHLP), derived from the white blood cells of crocodiles. In this research, three mutations were initially designed: LR-mut (RGSALTHLR), KR-mut (RGSAKTHLR), and WP-mut (RGSAWTHLP). The physicochemical characteristics of these peptides were assessed, revealing that KR-mut exhibited the most favorable biophysical properties. Subsequently, twenty molecular dynamics simulations were conducted for all peptides in pure water and at four different octanol concentrations (30 %, 50 %, 70 %, and 100 %) to evaluate their biophysical attributes. The findings from the 4000 ns molecular dynamics simulations revealed that the KR-mut exhibited reduced values of RMSD, the radius of gyration, solvent accessible surface area, and RMSF, while simultaneously showing an increased number of hydrogen bonds and interactions with water molecules. This peptide also showed the lowest free energy of solvation and the highest solubility across various octanol concentrations compared to the other peptides. The results obtained from the biophysical assessments and molecular dynamics simulations were consistent, resulting in the conclusion that KR-mut is expected to exhibit superior antibacterial activity compared to both the other mutated peptides and the wild type peptides. These theoretical findings were validated through experimental minimum inhibitory concentration (MIC) tests on gram-negative

Indexed as

Antimicrobial peptideMICMolecular dynamic simulationMutationOctanolRP9

Identifiers

PMID40034258
PMCPMC11872504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.